Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (5): 793-801. doi: 10.19723/j.issn.1671-167X.2023.05.004

Previous Articles     Next Articles

Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment

Huan-rui LIU1,Xiang PENG1,2,Sen-lin LI1,Xin GOU1,*()   

  1. 1. Department of Urology, The First Hospital of Chongqing Medical University, Chongqing 400016, China
    2. Chongqing Key Laboratory of Molecular Tumor and Epigenetics, Chongqing 400016, China
  • Received:2023-03-20 Online:2023-10-18 Published:2023-10-09
  • Contact: Xin GOU E-mail:gouxincq@163.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the correlation between the human epidermal growth factor receptor-2-related genes (HRGs) and survival prognosis of bladder cancer and to construct a predictive model for survival prognosis of bladder cancer patients based on HRGs. Methods: HRGs in bladder cancer were found by downloading bladder tumor tissue mRNA sequencing data and clinical data from the cancer genome atlas (TCGA), downloading HER-2 related genes from the molecular signatures database (MsigDB), and crossing the two databases. Further identifying HRGs associated with bladder cancer survival (P < 0.05) by using single and multi-factor Cox regression analysis and constructing HRGs risk score model (HRSM), the bladder cancer patients were categorized into high-risk and low-risk groups accor-ding to the median risk score. Survival analysis of the patients in high- and low-risk groups was conducted using R language and correlation of HRGs with clinical characteristics. A multi-factor Cox regression analysis was used to verify the independent factors affecting the prognosis of the patients with bladder cancer. The area under the curve (AUC) of the receiver operating characteristic curve (ROC) of HRSM was calculated, and a nomogram was constructed for survival prediction of the bladder cancer patients. Analysis of HRSM and patient immune cell infiltration correlation was made using the TIMER database. Results: A total of 13 HRGs associated with patient survival were identified in this study. Five genes (BTC, CDC37, EGF, PTPRR and EREG) were selected for HRSM by multi-factor Cox regression analysis. The 5-year survival rate of the bladder cancer patients in the high-risk group was significantly lower than that of the patients in the low-risk group. High expression of PTPRR was found to be significantly and negatively correlated with tumor grade and stage by clinical correlation analysis, while EREG was found to be the opposite; Increased expression of EGF was associated with high grade, however, the high expression ofCDC37showed the opposite result. And no significant correlation was found between BTC expression and clinical features. Correlation analysis of HRSM with immune cells revealed a positive correlation between risk score and infiltration of dendritic cells, CD8+T cells, CD4+T cells, neutrophils and macrophages. Conclusion: HRGs have an important role in the prognosis of bladder cancer patients and may serve as new predictive biomarkers and potential targets for treatment.

Key words: Bladder cancer, HER-2 related genes, Risk model, Prognosis, Immune cell infiltration

CLC Number: 

  • R737.1

Table 1

General clinical characteristics of patients with bladder cancer in the TCGA database"

CharacteristicsValue, n(%)
Age/year
  ≤65141 (37.7)
  >65233 (62.3)
Gender
  Female96 (25.7)
  Male278 (74.3)
Grade
  High354 (94.7)
  Low20 (5.3)
Clinical stage
  Ⅰ2 (0.5)
  Ⅱ105 (28.1)
  Ⅲ138 (36.9)
  Ⅳ129 (34.5)
T stage
  T01 (0.3)
  T13 (0.8)
  T2118 (31.6)
  T3194 (51.9)
  T458 (15.5)
N stage
  N0222 (59.4)
  N1-3126 (33.7)
  Nx26 (7.0)
M stage
  M0178 (47.6)
  M18 (2.1)
  Mx188 (50.3)

Figure 1

Single-factor Cox regression analysis of 13 HRGs associated with patient survival HRGs, HER-2 related genes."

Figure 2

Construction of HRSM for survival analysis A, distribution of patients based on risk scores; B, survival status for each patient (low risk, left side of the dashed line; high risk, right side of the dashed line); C, heat map of HRGs between low-risk groups (red) and high-risk groups (blue) (green, low expression level; red, high expression level); D, Kaplan-Meier survival curves for patients in the low-risk and high-risk groups. HRGs, HER-2 related genes; HRSM, HRGs risk score model."

Figure 3

Multi-factor Cox regression analysis of risk scores"

Figure 4

Correlation between HRGs and clinical A, relationship between the gene expression of HRSM and clinical stage of bladder cancer (the horizontal line inside the box plot indicates the median of gene expression); B, C, D, relationship between the gene expression of HRSM and TNM stage; E, relationship between the gene expression of HRSM and pathologic grade of bladder cancer. HRSM, HRGs risk score model; HRGs, HER-2 related genes; HG, high grade; LG, low grade. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant."

Figure 5

ROC curves for HRSM and general clinical features HRSM, HRGs risk score model; HRGs, HER-2 related genes; AUC, area under the curve; ROC, receiver operating characteristic curve."

Figure 6

Construction of a prognostic nomogram for bladder cancer patients based on HRGs HRGs, HER-2 related genes."

Figure 7

Calibration curves for prognostic nomograms The gray line indicates the idealized model, and the better the match with the gray line, the better the prediction ability. OS, overall survival."

Figure 8

Graph of the relationship between risk score and immune cell infiltration The closer the correlation value is to 1 or-1, the stronger the positive or negative correlation is. cor, correlation."

1 AneoniS , FerlayJ , SoerjomatarmI ,et al.Bladder cancer incidence and mortality: A global overview and recent trends[J].Eur Urol,2017,71(1):96-108.
doi: 10.1016/j.eururo.2016.06.010
2 NielsenME , SmithAB , MererAM ,et al.Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the Uni-ted States: 1988 to 2006[J].Cancer,2014,120(1):86-95.
doi: 10.1002/cncr.28397
3 CrispenPL , KusmartsevS .Mechanisms of immune evasion in bladder cancer[J].Cancer Immunol Immunother,2020,69(1):3-14.
doi: 10.1007/s00262-019-02443-4
4 Goossens-LaanCA , LeliveldAM , VerhoevenRH ,et al.Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer[J].Int J Cancer,2014,135(4):905-912.
doi: 10.1002/ijc.28716
5 Redondo-GonzalezE , de CastroLN , Moreno-SierraJ ,et al.Bladder carcinoma data with clinical risk factors and molecular mar-kers: A cluster analysis[J].Biomed Res Int,2015,2015,168682.
6 MoasserMM .The oncogene HER2 : Its signaling and transforming functions and its role in human cancer pathogenesis[J].Oncogene,2007,26(45):6469-6487.
doi: 10.1038/sj.onc.1210477
7 BegnamiMD , FukudaE , FregnaniJH ,et al.Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome[J].J Clin Oncol,2011,29(22):3030-3036.
doi: 10.1200/JCO.2010.33.6313
8 BangYJ , van CutsemE , FeyereislovaA ,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697.
doi: 10.1016/S0140-6736(10)61121-X
9 WolffAC , HammondME , HicksDG ,et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Patho-logists clinical practice guideline update[J].J Clin Oncol,2013,31(31):3997-4013.
doi: 10.1200/JCO.2013.50.9984
10 IyerG , Al-AhmadieH , SchultzN ,et al.Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer[J].J Clin Oncol,2013,31(25):3133-3140.
doi: 10.1200/JCO.2012.46.5740
11 BaiX , HeW , YinH ,et al.Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single-center experience[J].Exp Ther Med,2022,24(5):704.
doi: 10.3892/etm.2022.11640
12 LoiS , SirtaineN , PietteF ,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.
doi: 10.1200/JCO.2011.41.0902
13 StantonSE , AdamsS , DisisML .Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review[J].JAMA Oncol,2016,2(10):1354-1360.
doi: 10.1001/jamaoncol.2016.1061
14 JiaY , KodumudiKN , RamamoorthiG ,et al.Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway[J].Mol Ther,2021,29(4):1541-1556.
doi: 10.1016/j.ymthe.2020.12.037
15 WülfingC , MachielsJP , RichelDJ ,et al.A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma[J].Cancer,2009,115(13):2881-2890.
doi: 10.1002/cncr.24337
16 ShengX , YanX , WangL ,et al.Open-label, multicenter, phase Ⅱ study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma[J].Clin Cancer Res,2021,27(1):43-51.
doi: 10.1158/1078-0432.CCR-20-2488
17 ShengX , ZhouAP , YaoX ,et al.A phase Ⅱ study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma[J].J Clin Oncol,2019,37(Suppl 15):4509.
18 RushJS , PetersonJL , CeresaBP .Betacellulin (BTC) biases the EGFR to dimerize with ErbB3[J].Mol Pharmacol,2018,94(6):1382-1390.
doi: 10.1124/mol.118.113399
19 ShenT , YangT , YaoM ,et al.BTC as a novel biomarker contri-buting to EMT via the PI3K-AKT pathway in OSCC[J].Front Genet,2022,13,875617.
doi: 10.3389/fgene.2022.875617
20 DahlhoffM , WolfE , SchneiderMR .The ABC of BTC: Structural properties and biological roles of betacellulin[J].Semin Cell Dev Biol,2014,28,42-48.
doi: 10.1016/j.semcdb.2014.01.002
21 OlsenDA , KjaerIM , BrandslundI .Development of a three-plex single molecule immunoassay enabling measurement of the EGFR ligands amphiregulin, betacellulin and transforming growth factor alpha simultaneously in human serum samples[J].J Immunol Methods,2018,459,63-69.
doi: 10.1016/j.jim.2018.05.002
22 LeeYS , SongGJ , JunHS .Betacellulin-induced alpha-cell proli-feration is mediated by ErbB3 and ErbB4, and may contribute to beta-cell regeneration[J].Front Cell Dev Biol,2020,8,605110.
23 OlsenDA , BechmannT , ϕstergaardB ,et al.Increased concentrations of growth factors and activation of the EGFR system in breast cancer[J].Clin Chem Lab Med,2012,50(10):1809-1818.
24 PearlLH .Hsp90 and Cdc37: A chaperone cancer conspiracy[J].Curr Opin Genet Dev,2005,15(1):55-61.
doi: 10.1016/j.gde.2004.12.011
25 SerwetnykMA , BlaggBSJ .The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition[J].Acta Pharm Sin B,2021,11(6):1446-1468.
doi: 10.1016/j.apsb.2020.11.015
26 GrayPJ , Jr. , PrinceT , ChengJ ,et al.Targeting the oncogene and kinome chaperone CDC37[J].Nat Rev Cancer,2008,8(7):491-495.
doi: 10.1038/nrc2420
27 GhatakS , MisraS , TooleBP .Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells[J].J Biol Chem,2005,280(10):8875-8883.
doi: 10.1074/jbc.M410882200
28 HuangW , YeM , ZhangLR ,et al.FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation[J].Mol Cancer,2014,13,150.
doi: 10.1186/1476-4598-13-150
29 Esparís-OgandoA , MonteroJC , ArribasJ ,et al.Targeting the EGF/HER ligand-receptor system in cancer[J].Curr Pharm Des,2016,22(39):5887-5898.
doi: 10.2174/1381612822666160715132233
30 WangZ .ErbB receptors and cancer[J].Methods Mol Biol,2017,1652,3-35.
31 GarousiS , Jahanbakhsh-GodehkahrizS , EsfahaniK ,et al.Meta-analysis of EGF-stimulated normal and cancer cell lines to discover EGF-associated oncogenic signaling pathways and prognostic biomarkers[J].Iran J Biotechnol,2022,20(3):e3245.
32 LaczmanskaI , SasiadekMM .Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer[J].Acta Biochim Pol,2011,58(4):467-470.
33 MenigattiM , CattaneoE , Sabates-BellverJ ,et al.The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis[J].Mol Cancer,2009,8,124.
doi: 10.1186/1476-4598-8-124
34 WangY , CaoJ , LiuW ,et al.Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin[J].J Biol Chem,2019,294(48):18306-18323.
doi: 10.1074/jbc.RA119.010348
35 SuPH , LinYW , HuangRL ,et al.Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer[J].Oncogene,2013,32(1):15-26.
doi: 10.1038/onc.2012.29
36 MunkleyJ , LaffertyNP , KalnaG ,et al.Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells[J].BMC Cancer,2015,15,9.
doi: 10.1186/s12885-015-1012-8
37 ChengWL , FengPH , LeeKY ,et al.The role of EREG/EGFR pathway in tumor progression[J].Int J Mol Sci,2021,22(23):12828.
doi: 10.3390/ijms222312828
38 ZhangL , NanF , YangL ,et al.Differentially expressed EREG and SPP1 are independent prognostic markers in cervical squamous cell carcinoma[J].J Obstet Gynaecol Res,2022,48(7):1848-1858.
doi: 10.1111/jog.15265
39 LiuS , WangY , HanY ,et al.EREG-driven oncogenesis of head and neck squamous cell carcinoma exhibits higher sensitivity to erlotinib therapy[J].Theranostics,2020,10(23):10589-10605.
doi: 10.7150/thno.47176
40 XiaQ , ZhouY , YongH ,et al.Elevated epiregulin expression predicts poor prognosis in gastric cancer[J].Pathol Res Pract,2019,215(5):873-879.
doi: 10.1016/j.prp.2019.01.030
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[3] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[4] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[5] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[6] Zuoxiang LIU,Xiaowei CHEN,Houyu ZHAO,Siyan ZHAN,Feng SUN. Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 424-430.
[7] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[8] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[9] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[10] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[11] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
[12] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[13] Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269.
[14] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[15] Qian SU,Xin PENG,Chuan-xiang ZHOU,Guang-yan YU. Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 13-21.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd